Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to-severe ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the Phase IIb RELIEVE UCCD trial of duvakitug.

The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ‘Top Pick For 2025’ In the UC cohort of the RELIEVE UCCD study ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 monoclonal antibody targeting TL1A, for the ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...